New Biologics at EULAR 2014: Stop and Wait
(EULAR2014) Which candidate biologics for rheumatology are destined to pass "Go" and collect? A member of the audience at the recent conference presents his observations and comments.
Low Progression of Erosive Disease with T2T in Early PsA
Targeted treatment for psoriatic arthritis, already shown to improve disease activity markers, now associated with low rates of progression in joint erosion.
New Catalogue Sorts IgG4RD From Sjögren's
(EULAR 2014) IgG4-related disorder and Sjögren syndrome share some symptoms, but have different treatments. A new study involving registry and clinical research data shows how to tell them apart.
EULAR Releases Recommendations on Imaging Spondyloarthropathies
(EULAR 2014) Rheumatologists and radiologists from 11 countries have collaborated to draft 10 recommendations for imaging to diagnose axial and peripheral spondyloarthritis.
Gout and Sex: Different, and Not So Good
(EULAR 2014) New research finds erectile dysfunction common among gout patients, and distinctive differences between men and women in predisposing factors and treatment risks.
Unresolved RA Pain Threatens Treatment Success
(EULAR 2014) Predictors of continuing pain after rheumatoid arthritis treatment differ from those that predict inflammation. For TNF inhibitors at least, unresolved pain also contributes to treatment failure.
Belimumab Scores High Against SLE in Real Clinical Practice
(EULAR 2014) Based on physician's opinions and on some clinical indicators, the BAFF inhibitor belimumab is achieving impressive results against lupus in both the US and Germany.
By clicking Accept, you agree to become a member of the UBM Medica Community.